Coherus Oncology Q4 revenue misses estimates

Coherus Oncology

09/03/2026 20:31

Corrects Q4 EPS from continuing operations in Key Details table to -$0.39, from -$1.56

Overview

Oncology firm's Q4 revenue missed analyst expectations

LOQTORZI product sales more than doubled yr/yr, driven by higher patient demand

Company reduced debt by 90% from $480 mln to $38.8 mln over 2024-2025

Outlook

Coherus anticipates initial data readouts for tagmokitug studies in mid-2026

Company plans to begin mCRPC study with pasritamig in 2H 2026

Coherus expects first data from casdozokitug Phase 2 trial in mid-2026

Result Drivers

LOQTORZI SALES GROWTH - LOQTORZI net revenue more than doubled to $40.8 mln in 2025 from $19.1 mln in 2024, driven by higher patient demand and longer treatment durations

Company press release: ID:nGNXc55pb6

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Miss
$12.75 mln
$13.94 mln (6 Analysts)
Q4 EPS From Contops
-$0.39
Q4 Adjusted Net Income From Contops
Miss
-$40.42 mln
-$35.15 mln (5 Analysts)
Q4 Net Income
-$37.64 mln
Q4 Operating Income
-$45.88 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Coherus Oncology Inc is $6.00, about 229.7% above its March 6 closing price of $1.82

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)